ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
TAVI in young patients with bicuspid aortic valve stenosis: insight from the international AD-HOC registry.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TAVI in young patients: long-term outcomes beyond cusp morphology.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors.
Funding
Abstract
backgroundEvidence regarding transcatheter aortic valve implantation (TAVI) in young (≤ 75 years) low-risk patients with bicuspid aortic valve (BAV) stenosis deemed unsuitable for surgery is scarce.
objectivesTo investigate in-hospital and follow-up outcomes in this population compared with older or higher-risk patients.
methodsThis retrospective international registry included 980 patients with severe BAV stenosis undergoing TAVI, stratified in: Group I, < 69 years and Society of Thoracic Surgeons predicted mortality (STS-PROM) < 4 (N = 113); Group II, 69-75 years and STS-PROM < 4 (N = 173); Group III, > 75 years or STS-PROM ≥ 4 (N = 694). Endpoints included technical success, 30-day device success and safety, transcatheter heart valve (THV) function during follow-up, survival and freedom from transient ischemic attack (TIA)/stroke or heart failure hospitalization.
resultsTechnical success was comparable (Group I: 94.7%, Group II: 97.1%, Group III: 94.5%; P = 0.37), as were 30-day device success (P = 0.45) and safety (P = 0.29). Regression analyses revealed stable mean transvalvular gradients over follow-up with no differential temporal trends across groups (P = 0.93), and no association between follow-up time and PVL severity (P = 0.17); younger patients showed lower odds of mild PVL compared with older patients. Severe valve deterioration did not occur in Group I and II, versus 3 cases (0.4%) in Group III. Bioprosthesis valve failure rate remained < 2% and similar across groups (P = 0.53). Freedom from TIA/stroke or heart failure rehospitalization was higher in Group I (91.1%) and II (93.8%) than in Group III (81.0%, P = 0.006).
conclusionsTAVI in young, low-risk BAV patients deemed unsuitable for surgery showed favorable in-hospital outcomes comparable to those of older or higher-risk patients, with stable valve hemodynamics during follow-up.
Indexed as
Identifiers
42008143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.